StockData
Viridian Therapeutics, Inc.DE logo

Viridian Therapeutics, Inc.DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30260% above fair value
$29.96−1.48 (-4.71%)

Close on Nov 20, 2026Market cap $3.39BP/E –Yield –

Viridian Therapeutics, Inc.DE operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Viridian Therapeutics, Inc.DE's operating income for the twelve months ending Jun 30, 2026 was -$405.20M. For fiscal 2025 it was -$363.40M. The highest annual figure on record is -$197.00K in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$363.40M–
FY2024Dec 31, 2024-$299.04M–
FY2023Dec 31, 2023-$254.45M–
FY2022Dec 31, 2022-$134.30M–
FY2021Dec 31, 2021-$79.73M–
FY2020Dec 31, 2020-$110.38M–
FY2019Dec 31, 2019-$41.98M–
FY2018Dec 31, 2018-$33.08M–
FY2017Dec 31, 2017-$26.53M–
FY2016Dec 31, 2016-$16.99M–
FY2015Dec 31, 2015-$11.19M–
FY2014Dec 31, 2014-$6.87M–
FY2013Dec 31, 2013-$197.00K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$126.27M–
Q1 FY2026Mar 31, 2026-$116.17M–
Q4 FY2025Dec 31, 2025-$122.75M–
Q3 FY2025Sep 30, 2025-$40.01M–
Q2 FY2025Jun 30, 2025-$106.77M–
Q1 FY2025Mar 31, 2025-$93.87M–
Q4 FY2024Dec 31, 2024-$87.47M–
Q3 FY2024Sep 30, 2024-$83.48M–
Q2 FY2024Jun 30, 2024-$72.19M–
Q1 FY2024Mar 31, 2024-$55.90M–
Q4 FY2023Dec 31, 2023-$71.48M–
Q3 FY2023Sep 30, 2023-$51.22M–
Q2 FY2023Jun 30, 2023-$59.28M–
Q1 FY2023Mar 31, 2023-$72.47M–
Q4 FY2022Dec 31, 2022-$49.07M–
Q3 FY2022Sep 30, 2022-$29.79M–
Q2 FY2022Jun 30, 2022-$29.56M–
Q1 FY2022Mar 31, 2022-$25.89M–
Q4 FY2021Dec 31, 2021-$29.08M–
Q3 FY2021Sep 30, 2021-$14.13M–
Q2 FY2021Jun 30, 2021-$18.00M–
Q1 FY2021Mar 31, 2021-$18.52M–
Q4 FY2020Dec 31, 2020-$90.60M–
Q3 FY2020Sep 30, 2020-$5.41M–
Q2 FY2020Jun 30, 2020-$6.37M–
Q1 FY2020Mar 31, 2020-$8.00M–
Q4 FY2019Dec 31, 2019-$10.07M–
Q3 FY2019Sep 30, 2019-$11.23M–
Q2 FY2019Jun 30, 2019-$8.94M–
Q1 FY2019Mar 31, 2019-$11.74M–
Q4 FY2018Dec 31, 2018-$10.45M–
Q3 FY2018Sep 30, 2018-$9.15M–
Q2 FY2018Jun 30, 2018-$8.86M–
Q1 FY2018Mar 31, 2018-$4.62M–
Q4 FY2017Dec 31, 2017-$6.35M–
Q3 FY2017Sep 30, 2017-$5.89M–
Q2 FY2017Jun 30, 2017-$7.35M–
Q1 FY2017Mar 31, 2017-$6.94M–
Q4 FY2016Dec 31, 2016-$5.91M–
Q3 FY2016Sep 30, 2016-$4.08M–

More Viridian Therapeutics, Inc.DE figures

See a number that looks wrong?